Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
Authors
Elena Elimova
Princess Margaret Cancer Center, Toronto, ON, Canada;
Elena Elimova , Jaffer A. Ajani , Howard A. Burris III , Crystal S. Denlinger , Syma Iqbal , Yoon-Koo Kang , YEUL HONG Hong Kim , Keun-Wook Lee , Bruce Lin , Rutika Mehta , Do-Youn Oh , Sun Young Rha , Yong Mi Soel , Lisa Boyken , Jonathan E. Grim , Geoffrey Yuyat Ku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03929666
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 347)
DOI
10.1200/JCO.2023.41.4_suppl.347
Abstract #
347
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
First Author: Samuel J Klempner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
First Author: Tanios S. Bekaii-Saab
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
First Author: Keun-Wook Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
First Author: Manish A. Shah